BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

S1 Pharmaceuticals, Inc. Announces IND Filing of SIP-104 (Lorexys) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)


2/21/2012 10:22:49 AM

JERSEY CITY, N.J., Feb. 21, 2012 /PRNewswire/ -- S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Phase I-b clinical studies of SIP-104 (Lorexys). Lorexys is the Company's lead drug candidate for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Dysfunction (FSD).

Lorexys' clinical development plan is based on pharmacokinetic and safety data for a 505(b)(2) New Drug Application (NDA). Lorexys is a novel use fixed-dose combination (FDC) in an oral enteric formulation acting on the central nervous system (CNS) with therapeutic characteristics that benefit sufferers of sexual health disorders. It is intended as a treatment for HSDD both as a standalone and as an adjunct to testosterone therapy for the disorder.

"The IND filing for Lorexys is an important milestone for our Company," stated Nicolas G. Sitchon, Chief Executive Officer. "The Lorexys Clinical Development Program represents S1's entry into the significant Women's Sexual Health Disorders field with a lead drug candidate having several potential advantages over other treatment options in development."

On the condition of FDA endorsement of an approvable Investigational New Drug application for Lorexys, the Company will conduct Multiple Ascending Dose (MAD) safety, tolerability, and exploratory efficacy Phase I-b studies on Lorexys in 2012. Upon successful completion, the results from these studies will satisfy FDA requirements to commence Phase II studies for HSDD patients.

About S1 Pharmaceuticals, Inc.

S1 is an early-stage biopharmaceutical company developing therapeutic solutions for disorders of Women's Sexual Health. The most common type of Female Sexual Dysfunction (FSD) is a distressing loss of libido (lack of sexual interest) known as Hypoactive Sexual Desire Disorder (HSDD). S1 is developing its lead product, Lorexys, as an oral drug and will seek to demonstrate that Lorexys can be the first safe and effective treatment approved by the FDA for HSDD in women.

Contact:
press@s1pharma.com
(201) 839-0941

SOURCE S1 Pharmaceuticals, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES